NEW YORK, Oct 19 (Reuters) - Valeant Pharmaceuticals (N:VRX)
International Inc VRX.TO CEO J. Michael Pearson (L:PSON) said on Monday
that outside pressures are creating a new pricing environment
for all pharmaceutical companies and that Valeant expects to
keep increases to 10 percent or less next year.
During a conference call with investors in which he defended
the company's drug pricing strategy, Pearson said that Valeant
has begun during the past two years to increase sales volumes as
a percentage of growth compared with price increases.